Table 1. Characteristics of patients offering lung tissues.

C, control tissue; P, patient tissue; aPAH, associated PAH (collagen vascular disease); CTEPH, chronic thromboembolic pulmonary hypertension; PDE5i, phosphodiesterase type 5 inhibitor; ERA, endothelin receptor antagonist; Prostn, parenteral prostanoid; sGC, soluble guanylate cyclase; WHO, World Health Organization.

PatientDiagnosisAgeSexWHO classPAH therapy
Histology/immunoblotsC1Lobectomy (tumor)56MIINone
C2Unused transplant donor25MINone
C3Unused transplant donor38FINone
C4Unused transplant donor41FINone
P1aPAH34FIIIPDE5i + ERA
P2iPAH18MIVPDE5i + Prostn
P3iPAH39FIVERA + Prostn
P4iPAH31FIIIERA + Prostn
P5iPAH42FIIIPDE5i + ERA + Prostn
P6aPAH40MIVPDE5i + ERA + ProstnSIRT3 variantUCP2 variant
EVLP lung1aPAH62FIVPDE5i + ERA + ProstnG/GA/A
2aPAH61FIVPDE5i + ERA + ProstnG/AA/A
3iPAH32FIVPDE5i + ERA + ProstnG/GA/A
4iPAH43FIVPDE5i + ERA + ProstnG/AG/G
5CTEPH60MIVsGC stim + ProstnG/AA/A